Dare Bioscience, Inc. Revenue from Contract with Customer, Excluding Assessed Tax
Dare Bioscience, Inc. (DARE) reported Revenue from Contract with Customer, Excluding Assessed Tax of $187.55 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement › Revenue
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2026-08-13
- Dare Bioscience, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-06-30 was $187.55K.
- Dare Bioscience, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-03-31 was $152.46K, a 499.58% increase year-over-year.
- Dare Bioscience, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-12-31 was $1.02M.
- Dare Bioscience, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-09-30 was $2.26K, a 94.57% decline year-over-year.
- Dare Bioscience, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2025 was $1.03M, a 10429.36% increase from fiscal 2024.
- Dare Bioscience, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2024 was $9.78K, a 99.65% decline from fiscal 2023.
- Dare Bioscience, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2023 was $2.81M, a 71.92% decline from fiscal 2022.
- Dare Bioscience, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2022 was $10.00M.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 1 month | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $187.55K 10-Q · filed 2026-08-13 | $340.00K 10-Q · filed 2026-08-13 | $1.36M derived: sum of 3 quarters · filed 2026-08-13 | $1.37M derived: sum of 4 quarters · filed 2026-08-13 | |
| 2026-03-31 | $152.46K 10-Q · filed 2026-05-14 | $1.18M derived: sum of 2 quarters · filed 2026-05-14 | $1.18M derived: sum of 3 quarters · filed 2026-05-14 | $1.16M derived: sum of 4 quarters · filed 2026-08-13 | |
| 2025-12-31 | $1.02M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $1.03M derived: sum of 2 quarters · filed 2026-03-26 | $1.00M derived: sum of 3 quarters · filed 2026-08-13 | $1.03M 10-K · filed 2026-03-26 | |
| 2025-09-30 | $2.26K 10-Q · filed 2025-11-13 | -$18.91K derived: sum of 2 quarters · filed 2026-08-13 | $6.52K 10-Q · filed 2025-11-13 | -$57.13K derived: sum of 4 quarters · filed 2026-08-13 | |
| 2025-06-30 | -$21.17K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $4.25K 10-Q · filed 2026-08-13 | -$59.39K derived: sum of 3 quarters · filed 2026-08-13 | -$17.70K derived: sum of 4 quarters · filed 2026-08-13 | |
| 2025-03-31 | $25.43K 10-Q · filed 2026-05-14 | -$38.22K derived: sum of 2 quarters · filed 2026-05-14 | $3.47K derived: sum of 3 quarters · filed 2026-05-14 | $25.91K derived: sum of 4 quarters · filed 2026-05-14 | |
| 2024-12-31 | -$63.65K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | -$21.96K derived: sum of 2 quarters · filed 2026-03-26 | $482.00 derived: sum of 3 quarters · filed 2026-03-26 | $9.78K 10-K · filed 2026-03-26 | |
| 2024-09-30 | $41.69K 10-Q · filed 2025-11-13 | $64.13K derived: sum of 2 quarters · filed 2025-11-13 | $73.43K 10-Q · filed 2025-11-13 | $1.88M derived: sum of 4 quarters · filed 2025-11-13 | |
| 2024-06-30 | $22.44K 10-Q · filed 2025-08-14 | $31.74K 10-Q · filed 2025-08-14 | $1.84M derived: sum of 3 quarters · filed 2025-08-14 | $2.84M derived: sum of 4 quarters · filed 2025-08-14 | |
| 2024-03-31 | $9.30K 10-Q · filed 2025-05-13 | $1.82M derived: sum of 2 quarters · filed 2025-05-13 | $2.82M derived: sum of 3 quarters · filed 2025-05-13 | $2.82M derived: sum of 4 quarters · filed 2025-05-13 | |
| 2023-12-31 | $1.81M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $2.81M derived: sum of 2 quarters · filed 2025-03-31 | $2.81M derived: sum of 3 quarters · filed 2025-03-31 | $2.81M 10-K · filed 2025-03-31 | |
| 2023-09-30 | $1.00M 10-Q · filed 2023-11-09 | $1.00M derived: sum of 2 quarters · filed 2024-08-12 | $1.00M 10-Q · filed 2023-11-09 | $1.00M derived: sum of 4 quarters · filed 2024-08-12 | |
| 2023-06-30 | $0.00 10-Q · filed 2024-08-12 | $0.00 10-Q · filed 2024-08-12 | $0.00 derived: sum of 3 quarters · filed 2024-08-12 | $0.00 derived: sum of 4 quarters · filed 2024-08-12 | |
| 2023-03-31 | $0.00 10-Q · filed 2024-05-14 | $0.00 derived: sum of 2 quarters · filed 2024-05-14 | $0.00 derived: sum of 3 quarters · filed 2024-05-14 | $10.00M derived: sum of 4 quarters · filed 2024-05-14 | |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $0.00 derived: sum of 2 quarters · filed 2023-11-09 | $10.00M derived: sum of 3 quarters · filed 2023-11-09 | $10.00M 10-K · filed 2023-03-30 | |
| 2022-09-30 | $0.00 10-Q · filed 2023-11-09 | $10.00M derived: sum of 2 quarters · filed 2023-11-09 | $10.00M 10-Q · filed 2023-11-09 | ||
| 2022-06-30 | $10.00M 10-Q · filed 2023-08-10 | $10.00M 10-Q · filed 2023-08-10 | |||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $0.00 derived: sum of 2 quarters · filed 2023-03-30 | $0.00 derived: sum of 3 quarters · filed 2023-03-30 | $0.00 10-K · filed 2023-03-30 | |
| 2021-09-30 | $0.00 10-Q · filed 2022-11-10 | $0.00 derived: sum of 2 quarters · filed 2022-11-10 | $0.00 10-Q · filed 2022-11-10 | ||
| 2021-06-30 | $0.00 10-Q · filed 2022-08-09 | $0.00 10-Q · filed 2022-08-09 | |||
| 2020-04-30 | $731.00K 10-Q · filed 2020-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |